This trial is active, not recruiting.

Condition recurrent prostate cancer
Treatment mri-guided biopsy
Sponsor University Health Network, Toronto
Collaborator U.S. Army Medical Research and Materiel Command
Start date October 2006
End date May 2015
Trial size 90 participants
Trial identifier NCT00775866, Award Number W81XWH-05-1-0570, Proposal Number PC050204, UHN REB 05-0641-C


In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation therapy in order to map out the location of the recurrence. Using this technique, we will be able to measure the accuracy of MR images in identifying the site of tumour recurrence.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose diagnostic
mri-guided biopsy
Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.

Primary Outcomes

The primary endpoint is a preliminary estimate of the diagnostic accuracy of MRI in identifying sites of recurrent tumor after radiotherapy for prostate cancer.
time frame: at the end of the evaluation phase

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Biochemical failure > 18 months after definitive external beam radiotherapy (ASTRO definition - revised version 2006: rise by 2 ng/mL or more above the nadir PSA) - PSA <20 prior to initial course of external beam radiotherapy - PSADT >3 months at failure - Age ≥ 18 years - ECOG performance status 0 or 1 with >10 year life expectancy - Fit for local anaesthesia - Informed consent: Exclusion Criteria: - Contraindications to MRI - Severe claustrophobia - Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding brachytherapy - Previous brachytherapy - Active hormonal therapy - Radiologic evidence of LN or distant metastases - Other urinary or medical conditions deemed by the PI or associates to make the patient ineligible for MRI-guided prostate biopsy. - Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or previous colorectal surgery - Contraindications to conscious sedation - Contraindication to IV Gadolinium administration - latex allergy

Additional Information

Official title MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy
Principal investigator Peter Chung, MB ChB
Description This study involves the technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table. We primarily hypothesize that the integration of diagnostic and interventional MRI enables needle biopsy targeting to foci of tumor recurrence after radiotherapy, and will enable a determination of the diagnostic accuracy of MRI in mapping sub-sites of tumor recurrence after radiotherapy. RELEVANCE TO PUBLIC HEALTH: Patients with recurrence of their prostate cancer after radiotherapy currently face difficult choices. Standard second line treatments target the entire prostate gland and are associated many side effects. This study will directly improve the detection, spatial delineation, and characterization of prostate cancer persistence after radiotherapy. If anatomic patterns of disease persistence are found across patients, radiation delivery techniques will be suitably modified, which may translate to improved cure rates. Importantly, this study will establish a procedural platform for MRI-guidance of minimally invasive local salvage therapies. By precisely focusing salvage therapy to sites of tumor persistence within the prostate gland, side effects may be reduced in the future.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by University Health Network, Toronto.